Overall, compared with placebo, allocation to an SGLT2 inhibitor reduced the risk of the composite outcome of cardiovascular death or hospitalisation for heart failure by 23% (RR 0·77, 95% CI 0·74–0·81; figure 3). This evidence concerns the gene SLC5A2 and heart failure.